EGFR mutation status, treatment patterns, and outcomes in resectable early-stage non-small cell lung cancer prior to adjuvant EGFR-TKI approval: An international real-world study.

Abstract excerpt

OBJECTIVES: Historically, resection followed by chemotherapy was standard treatment for stage II-III non-small cell lung cancer (NSCLC) and selected patients with stage IB disease. However, recurrence was common post-resection. Genomic characterization of early-stage NSCLC and precision medicine have since provided more effective therapies. Real-world evidence prior to practice-changing approvals aids...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Aged, 80 and over
• Share to Carcinoma, Non-Small-Cell Lung